The Vertex Pharmaceuticals Incorporated (VRTX) Stock Rating Upgraded by Vetr Inc.

The Vertex Pharmaceuticals Incorporated (VRTX) Stock Rating Upgraded by Vetr Inc.

A number of other research firms have also recently commented on VRTX. Robert W. Baird reaffirmed an “outperform” rating and issued a $115.00 target price on shares of Vertex Pharmaceuticals in a research report on Wednesday, March 29th. BMO Capital Markets raised shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the company from $89.67 to $100.00 in a research report on Wednesday, March 29th. Zacks Investment Research cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, April 10th. JMP Securities reissued an “outperform” rating and set a $121.00 price target (up previously from $115.00) on shares of Vertex Pharmaceuticals in a research report on Friday, March 31st. Finally, Stifel Nicolaus increased their price target on shares of Vertex Pharmaceuticals from $100.00 to $129.00 and gave the stock a “buy” rating in a research report on Wednesday, March 29th. Nine equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $117.02.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was upgraded by equities research analysts at Vetr from a “strong sell” rating to a “sell” rating in a research note issued to investors on Monday, May 15th. The firm presently has a $102.09 price target on the pharmaceutical company’s stock. Vetr‘s price target would indicate a potential downside of 21.41% from the company’s current price.

Shares of Vertex Pharmaceuticals (NASDAQ VRTX) opened at 129.90 on Monday. Vertex Pharmaceuticals has a 12-month low of $71.46 and a 12-month high of $130.00. The stock’s 50 day moving average is $117.91 and its 200-day moving average is $95.24. The company has a market capitalization of $32.35 billion, a P/E ratio of 181.17 and a beta of 0.79.

In other Vertex Pharmaceuticals news, SVP Paul M. Silva sold 1,688 shares of the firm’s stock in a transaction on Wednesday, March 29th. The stock was sold at an average price of $106.30, for a total value of $179,434.40. Following the completion of the sale, the senior vice president now owns 21,759 shares of the company’s stock, valued at $2,312,981.70. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Amit Sachdev sold 80,500 shares of the firm’s stock in a transaction on Wednesday, March 29th. The shares were sold at an average price of $107.63, for a total value of $8,664,215.00. Following the completion of the sale, the executive vice president now directly owns 105,054 shares of the company’s stock, valued at approximately $11,306,962.02. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 272,429 shares of company stock valued at $31,346,164. Corporate insiders own 1.90% of the company’s stock. Large investors have recently added to or reduced their stakes in the stock. Korea Investment CORP increased its stake in Vertex Pharmaceuticals by 225.3% in the first quarter. Korea Investment CORP now owns 950 shares of the pharmaceutical company’s stock worth $104,000 after buying an additional 658 shares during the period. Guardian Life Insurance Co. of America boosted its position in shares of Vertex Pharmaceuticals by 0.6% in the first quarter. Guardian Life Insurance Co. of America now owns 956 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 6 shares in the last quarter. FUKOKU MUTUAL LIFE INSURANCE Co boosted its position in shares of Vertex Pharmaceuticals by 7.7% in the fourth quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,400 shares of the pharmaceutical company’s stock worth $103,000 after buying an additional 100 shares in the last quarter. Sterling Global Strategies LLC purchased a new position in shares of Vertex Pharmaceuticals during the first quarter worth $200,000. Finally, Pitcairn Co. purchased a new position in shares of Vertex Pharmaceuticals during the first quarter worth $218,000. 94.85% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Company Profile Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:VRTX”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

To view Vetr’s full report, visit Vetr’s official website.

Related posts

Leave a Comment